Early outcome of the effect of phosphodiesterase-5 inhibitor on pulmonary hypertension in patients undergoing mitral valve surgery
Keywords:
Phosphodiesterase-5 inhibitor, Pulmonary hypertension, Mitral valve surgeryAbstract
Background: The most frequent reason for pulmonary hypertension is left-sided cardiac disease. In certain cases, pulmonary arterial vasoconstriction & vascular remodeling may result in a superimposed active component that raises pulmonary arterial pressure even further. When PHTN is present, individuals with left-sided cardiac disease have a poorer prognosis. According to recent research, sildenafil, a phosphodiesterase-5 inhibitor, is a useful medication for treating pulmonary hypertension in patients with left-sided heart disease. Objective: To investigate how sildenafil works for pulmonary hypertension in patients with mitral valve disease. Patients and Methods: This study was conducted between 2015 & 2019 at Cairo University's Kasr El Aini Faculty of Medicine's Department of Cardiothoracic Surgery with local ethical committee permission. One hundred adults studied cases with mitral valve lesions & PHTN who had undergone mitral valve surgery were enrolled. Two groups of fifty studied cases each were assigned, & their preoperative risk factors were appropriately matched. studied cases in Group A (no=50) & pulmonary artery pressure (50-80mmHg) received sildenafil citrate.
Downloads
References
Abdollahi M, Fooladian F, Emani B. Protection by sildenafil and theophylline of lead acetate-induced oxidative stress in rat submandibular gland and saliva. Hum Exp Toxicol. 2003; 22:587–592. DOI: https://doi.org/10.1191/0960327103ht399oa
Atwood CW, Jr, McCrory D, Garcia JG. Pulmonary artery hypertension and sleep-disordered breathing: ACCP evidence-based clinical practice guidelines. Chest. 2004; 126:72S-77S. DOI: https://doi.org/10.1378/chest.126.1_suppl.72S
Badesch DB, Raskob GE, Elliott CG. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010; 137:376-387. DOI: https://doi.org/10.1378/chest.09-1140
Bharani A, Patel A, Jitendra S. Efficacy and Safety of PDE-5 Inhibitor Tadalafil in Pulmonary Arterial Hypertension. Indian Heart Journal, 2007; 59:323-328
Ghanem H, El Ashmawi HS, Marei T, Bakry MA. Efficacy of Sildenafil in the management of severe pulmonary hypertension in patients with rheumatic mitral valve disease undergoing mitral valve surgery. EJCTA. 2009; 3(2):67-74.
Ghofrani HA, Pepke-Zaba J, Barbera JA. Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J Am Coll Cardiol. 2004; 43:68-72. DOI: https://doi.org/10.1016/j.jacc.2004.02.031
Ghofrani HA, Rose F, Schermuly RT. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol. 2003; 42:158–164. DOI: https://doi.org/10.1016/S0735-1097(03)00555-2
Ghofrani HA, Wiedemann R, Rose F. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomized controlled trial. Lancet. 2002; 360:895–900. DOI: https://doi.org/10.1016/S0140-6736(02)11024-5
Ghoreishi M, Evans CF, DeFilippi CR, Hobbs G, Young CA, Griffith BP, Gammie JS. Pulmonary hypertension adversely affects short- and long-term survival after mitral valve operation for mitral regurgitation: Implications for timing of surgery. J Thorac Cardiovasc Surg. 2011; 142:1439-52. DOI: https://doi.org/10.1016/j.jtcvs.2011.08.030
Kloner R, Mitchell M, Emmick J. Cardiovascular effects of tadalafil. Am J Cardiol. 2003; 92: 37–46. DOI: https://doi.org/10.1016/S0002-9149(03)00074-2
Kloner R. Cardiovascular Effects of the 3 Phosphodiesterase-5 Inhibitors Approved for the Treatment of Erectile Dysfunction. Circulation. 2004;110:3149-3155. DOI: https://doi.org/10.1161/01.CIR.0000146906.42375.D3
Lepore JJ, Maroo A, Bigatello LM. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. Chest. 2001; 127:1647–1653. DOI: https://doi.org/10.1378/chest.127.5.1647
Macnee W. Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1994; 150:833-852. DOI: https://doi.org/10.1164/ajrccm.150.3.8087359
Madden B, Crerar-Gilbert A. Pulmonary hypertension and sildenafil. Br J Anaesth. 2005; 95:562-7. DOI: https://doi.org/10.1093/bja/aei599
Mehta S. Sildenafil for pulmonary arterial hypertension: exciting, but protection required. Chest. 2003; 123:989-992. DOI: https://doi.org/10.1378/chest.123.4.989
Michelakis ED, Tymchak W, Noga M. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation. 2003; 108: 2066-2069. DOI: https://doi.org/10.1161/01.CIR.0000099502.17776.C2
Ramani GV, Park MH. Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension. Drug Design, Development and Therapy 2010:4 61–70. DOI: https://doi.org/10.2147/DDDT.S6208
Ross R, Binder TH. Monitoring of Invasive Procedures – The Role of Echocardiography in Cathlab and Operating Room. J Clin Basic Cardiol. 2003; 5: 139–43.
Shim T, Rohit M, Grover A. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J. 2006; 151:851.e1–851e5. DOI: https://doi.org/10.1016/j.ahj.2005.09.006
Trachte AL, Lobato EB, Urdaneta F, Hess PJ, Klodell CT, Martin TD, Staples ED, Beaver TM. Oral sildenafil reduces pulmonary hypertension after cardiac surgery. Ann Thorac Surg. 2005; 79:194–7. DOI: https://doi.org/10.1016/j.athoracsur.2004.06.086
Weimann R, Opitz CF, Anker SD, Winkler J, Hoffken G, Kleber FX, Sharma R, Hummel M, Hetzer R, Ewert R. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation. 2002; 106:319–324. DOI: https://doi.org/10.1161/01.CIR.0000022687.18568.2A
Wheeler W, Hayes S, Nguyen N, Cilla AM, Rybowicz J, Jones CC, Ramsay MA, Hall SA, Meyer D, Jessen ME. Sildenafil- a possible treatment for acute pulmonary hypertension during cardiac surgery. BUMC Procceedings. 2002;15:13–15. DOI: https://doi.org/10.1080/08998280.2002.11927806
Zwissler B. Acute right heart failure: Etiology pathophysiology diagnosis therapy. Anaesthesist. 2000; 49:788–808. DOI: https://doi.org/10.1007/s001010070052
Published
How to Cite
Issue
Section
Copyright (c) 2021 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
